ProCE Banner Activity

CME

Navigating the Complex Treatment Landscape in Relapsed/Refractory Myeloma

Multimedia

In this on-demand webcast from a live webinar, Paul G. Richardson, MD; Natalie S. Callander, MD; and Noopur Raje, MD, discuss recent advances in new and emerging therapies for patients with relapsed/refractory multiple myeloma.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: October 12, 2022

Expiration: October 11, 2023

No longer available for credit.

Share

Faculty

Natalie S. Callander

Natalie S. Callander, MD

Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Noopur Raje

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Paul G. Richardson

Paul G. Richardson, MD

Associate Professor of Medicine
Harvard Medical School
Clinical Director
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Medical Learning Institute, Inc. in partnership with Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from

Janssen administered by Scientific Affairs

Karyopharm Therapeutics Inc.

Regeneron Pharmaceuticals, Inc.

Target Audience

This educational program is intended for hematologists, medical oncologists, nurses, pharmacists, and other healthcare professionals who treat patients with R/R MM

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan therapeutic strategies for patients with R/R MM based on currently available data, individual patient and disease characteristics, and response to and tolerance of prior therapy
  • Evaluate the efficacy and safety evidence of novel combination therapeutic regimens for patients with R/R MM
  • Mitigate treatment-related symptoms associated with new targeted therapies in patients with R/R MM
  • Identify patients with R/R MM who would be eligible for enrollment on clinical trials

Disclosure

Disclosure and Conflict of Interest Policy

Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and Clinical Care Options, LLC (CCO). Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Paul G. Richardson, MD

Associate Professor of Medicine
Harvard Medical School
Clinical Director
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Paul G. Richardson, MD: consultant/advisor/speaker: AstraZeneca, Celgene/Bristol Myers Squibb, GlaxoSmithKline, Karyopharm, Novartis, Oncopeptides, Sanofi, Secura Bio, Takeda; researcher: Celgene/Bristol Myers Squibb, Karyopharm, Oncopeptides, Takeda.

Faculty Disclosure

Primary Author

Natalie S. Callander, MD

Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Natalie S. Callander, MD, has no relevant financial relationships to disclose.

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Noopur Raje, MD: consultant/advisor/speaker: AbbVie, Amgen, Bluebird Bio, Bristol-Myers Squibb, Caribou Biosciences & Immuneel, Janssen, Pfizer, Sanofi, Takeda; researcher: Bluebird Bio.

Planner/Manager Text

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationships to disclose.

Staff Disclosure

Staff

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no relevant financial relationships to disclose.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant financial relationships to disclose.

Ramya Moorthy,

Clinical Editor

Ramya Moorthy, has no relevant financial relationships to disclose.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant financial relationships to disclose.

Brian Purves, PharmD, MBA

Brian Purves, PharmD: The following relationships have ended within the last 24 months: Employee of AstraZeneca with focus in Medical Information for Respiratory Inhaled-Symbicort.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.

Kristen Rosenthal, PhD

Clinical Editor

Kristen M. Rosenthal, PhD, has no relevant financial relationships to disclose.

Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN

Nurse Practitioner
Department of Urology
University of Virginia
Charlottesville, Virginia

Terran Sims, MSN, ACNP-C, CNN, COCN-C: consultant/advisor/speaker: Coloplast Corp.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley, MSc, has no relevant financial relationships to disclose.

Saranya Vijayakumar, PhD

Clinical Editor

Saranya Vijayakumar, PhD, has no relevant financial relationships to disclose.

Accreditation

Joint Accreditation Statement

Physician Continuing Medical Education

Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 12, 2022, through October 11, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve the knowledge and competence of learners in selecting individualized treatments for patients with R/R MM.